← Back to Patent Explorer
US4259338A Expired / Lapsed US ⏱️ 0.0 years remaining

Benzofuranyl-tetrahydropyridines and -piperidines, their acid addition salts and antidepressant preparations thereof

Assignee: Novartis Corp
•
Filing: 1980-04-14
•
Granted: 1981-03-31
•
Expires: 2000-04-14
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention provides new benzofuranyl-tetrahydropyridines and -piperidines of the general formula I ##STR1## in which R 1 and R 2 independently of one another are hydrogen or lower alkyl or together are lower alkylene, R 3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cyclo-lower alkyl or cyclo-lower alkyl-lower alkyl and Y 1 and Y 2 are each hydrogen or together are an additional bond, and the ring A is not further substituted or is further substituted by lower alkyl, lower alkoxy, halogen with an atomic number not more than 35, cyano or hydroxyl and the pharmaceutically acceptable acid addition salts thereof, and antidepressant preparations containing these compounds. The compounds according to the invention have valuable pharmacological properties. In particular, they inhibit the absorption of serotonin by mesencephalic synaptosomes, the serotonin depletion induced in the brain of rats by H 75/12, the absorption of noradrenalin by mesencephalic synaptosomes in rats and the noradrenalin depletion induced in the brain of rats by H 77/77. In the same dosage they also effect inhibition of monoamino-oxidase in the brain of rats and in the liver of rats. Furthermore, they intensify the "head twitch" induced by 5-hydroxy-tryptophan, and are distinguished by good tolerance. The compounds of the general formula I and their pharmaceutically acceptable acid addition salts can therefore be used as psychopharmaceuticals and in particular as antidepressants.

Inventors

  • 👤 Romeo Paioni
  • 👤 Walter Schilling
  • 👤 Raymond Bernasconi

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 14:53
CPC Classifications
C; C07; C07D; C07D307/00; C07D307/77; C07D307/78; C07D307/79; A; A61; A61P; A61P25/00; A61P25/24; A61P25/26; C07D307/86; C07D307/91

Claims Analysis

Total Claims: 27
Claim 1
Independent Claim 97 words
A compound of the formula I ##STR14## in which R 1 and R 2 independently of one another are hydrogen or lower alkyl or together are lower alkylene, R 3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cyclo-lower alkyl or cyclo-lower alkyl-lower alkyl and Y 1 and Y 2 are each hydrogen or together are an additional bond, and the ring A is not further substituted or is further substituted by lower alkyl, lower alkoxy, halogen with an atomic number of not more than 35, cyano or hydroxyl, or a pharmaceutically acceptable acid addition salt thereof.
Claim 2
Dependent Claim 97 words
A compound of the formula I ##STR14## in which R 1 and R 2 independently of one another are hydrogen or lower alkyl or together are lower alkylene, R 3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cyclo-lower alkyl or cyclo-lower alkyl-lower alkyl and Y 1 and Y 2 are each hydrogen or together are an additional bond, and the ring A is not further substituted or is further substituted by lower alkyl, lower alkoxy, halogen with an atomic number of not more than 35, cyano or hydroxyl, or a pharmaceutically acceptable acid addition salt thereof.
Claim 3
Dependent Claim 75 words
A compound according to claim 1 corresponding to the formula I given in claim 1, in which R 1 , R 2 , R 3 , Y 1 and Y 2 are as defined in claim 1 and the ring A is not further substituted or is further monosubstituted by lower alkyl, lower alkoxy, halogen with an atomic number of not more than 35, cyano or hydroxyl, or a pharmaceutically acceptable acid addition salt thereof.
Claim 4
Dependent Claim 90 words
A compound according to claim 1 corresponding to the general formula I given in claim 1, in which R 1 is methyl and R 2 is hydrogen or methyl, or R 1 and R 2 together are tetramethylene, R 3 , Y 1 and Y 2 are as defined in claim 1 and the ring A is not further substituted or is further monosubstituted by lower alkyl, lower alkoxy, halogen with an atomic number of not more than 35, cyano or hydroxyl, or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Dependent Claim 109 words
A compound according to claim 1 corresponding to the general formula I given in claim 1, in which R 1 is methyl and R 2 is methyl or hydrogen, or R 1 and R 2 together are tetramethylene, R 3 is hydrogen or a radical according to the definition given in claim 1, which has not more than 4 carbon atoms, Y 1 and Y 2 are as defined in claim 1 and the ring A is not further substituted or is further monosubstituted by lower alkyl, lower alkoxy, halogen with an atomic number of not more than 35 or cyano, or a pharmaceutically acceptable acid addition salt thereof.
Claim 6
Dependent Claim 102 words
A compound according to claim 1 corresponding to the general formula I given in claim 1, in which R 1 is methyl and R 2 is methyl or hydrogen, or R 1 and R 2 together are tetramethylene, R 3 is hydrogen, lower alkyl containing not more than 4 carbon atoms, allyl, 2-propynyl, cyclopropyl or cyclopropylmethyl, Y 1 and Y 2 are as defined in claim 1 and the ring A is not further substituted or is further monosubstituted by methyl, methoxy, halogen with an atomic number of not more than 35 or cyano, or a pharmaceutically acceptable acid addition salt thereof.
Claim 7
Dependent Claim 97 words
A compound according to claim 1 corresponding to the general formula I given in claim 1, in which R 1 and R 2 are each methyl or together are tetramethylene, R 3 is hydrogen, methyl or 2-propynyl, and Y 1 and Y 2 are each a hydrogen atom, the ring A is not further substituted or is further monosubstituted by methyl, methoxy, halogen with an atomic number of not more than 35 or cyano, and the nitrogen-containing ring is in the 5-position or 6-position of the benzofuran ring system, or a pharmaceutically acceptable acid addition salt thereof.
Claim 8
Dependent Claim 17 words
A compound according to claim 1 which is 4-(2,3-dimethyl-5-benzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 9
Dependent Claim 17 words
A compound according to claim 1 which is 4-(2,3-dimethyl-6-benzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 10
Dependent Claim 17 words
A compound according to claim 1 which is 4-(6,7,8,9-tetrahydro-2-dibenzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 11
Dependent Claim 17 words
A compound according to claim 1 which is 1-methyl-4-(2,3-dimethyl-5-benzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 12
Dependent Claim 17 words
A compound according to claim 1 which is 1-methyl-4-(2,3-dimethyl-6-benzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 13
Dependent Claim 17 words
A compound according to claim 1 which is 1-(2-propynyl)-4-(2,3-dimethyl-5-benzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 14
Dependent Claim 17 words
A compound according to claim 1 which is 4-(2,3-dimethyl-7-methoxy-5-benzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 15
Dependent Claim 17 words
A compound according to claim 1 which is 4-(2,3,7-trimethyl-5-benzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 16
Dependent Claim 17 words
A compound according to claim 1 which is 4-(2,3-dimethyl-7-brom-5-benzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 17
Dependent Claim 17 words
A compound according to claim 1 which is 4-(2,3-dimethyl-7-cyano-5-benzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 18
Dependent Claim 17 words
A compound according to claim 1 which is 1-methyl-4-(6,7,8,9-tetrahydro-2-dibenzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 19
Dependent Claim 17 words
A compound according to claim 1 which is 1-(2-propynyl)-4-(6,7,8,9-tetrahydro-2-dibenzofuranyl)-piperidine or a pharmaceutically acceptable acid addition salt thereof.
Claim 20
Dependent Claim 125 words
A pharmaceutical preparation for the treatment of emotional depression comprising a therapeutically effective amount of a compound according to claim 1 and corresponding to the formula I ##STR15## in which R 1 and R 2 independently of one another are hydrogen or lower alkyl or together are lower alkylene, R 3 is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, cyclo-lower alkyl or cyclo-lower alkyl-lower alkyl and Y 1 and Y 2 are each hydrogen or together are an additional bond, and the ring A is not further substituted or is further substituted by lower alkyl, lower alkoxy, halogen with an atomic number of not more than 35, cyano or hydroxyl, or of a pharmaceutically acceptable acid addition salt thereof, and at least one pharmaceutical carrier.
Claim 21
Dependent Claim 87 words
A pharmaceutical preparation according to claim 19, wherein a therapeutically effective amount of a compound corresponding to the formula I given in claim 19, in which R 1 , R 2 , R 3 , Y 1 and Y 2 are as defined in claim 19, and the ring A is not further substituted or is further monosubstituted by lower alkyl, lower alkoxy, halogen with an atomic number of not more than 35, cyano or hydroxyl, or of a pharmaceutically acceptable acid addition salt thereof is present.
Claim 22
Dependent Claim 111 words
A pharmaceutical preparation according to claim 19, wherein a therapeutically effective amount of a compound corresponding to the formula I given in claim 19, in which R 1 is methyl and R 2 is methyl or hydrogen, or R 1 and R 2 together are tetramethylene, R 3 is hydrogen, lower alkyl containing not more than 4 carbon atoms, allyl, 2-propynyl, cyclopropyl or cyclopropylmethyl, Y 1 and Y 2 are as defined in claim 19 and the ring A is not further substituted or is further monosubstituted by methyl, methoxy, halogen with an atomic number of not more than 35 or cyano, or of a pharmaceutically acceptable salt thereof is present.
Claim 23
Dependent Claim 108 words
A pharmaceutical preparation according to claim 19, wherein a therapeutically effective amount of a compound corresponding to the formula I given in claim 19, in which R 1 and R 2 are each methyl or together are tetramethylene, R 3 is hydrogen, methyl or 2-propynyl, and Y 1 and Y 2 are each a hydrogen atom, the ring A is not further substituted or is further monosubstituted by methyl, methoxy, halogen with an atomic number of not more than 35 or cyano, an the nitrogen-containing ring is in the 5-position or 6-position of the benzofuran ring system, or of a pharmaceutically acceptable acid addition salt thereof is present.
Claim 24
Dependent Claim 25 words
A pharmaceutical preparation according to claim 19, wherein a therapeutically effective amount of 4-(2,3-dimethyl-5-benzofuranyl)-piperidine or of a pharmaceutically acceptable acid addition salt thereof is present.
Claim 25
Dependent Claim 25 words
A pharmaceutical preparation according to claim 19, wherein a therapeutically effective amount of 4-(2,3-dimethyl-6-benzofuranyl)-piperidine or of a pharmaceutically acceptable acid addition salt thereof is present.
Claim 26
Dependent Claim 25 words
A pharmaceutical preparation according to claim 19, wherein a therapeutically effective amount of 4-(6,7,8,9-tetrahydro-2-dibenzofuranyl)-piperidine or of a pharmaceutically acceptable acid addition salt thereof is present.
Claim 27
Dependent Claim 54 words
A method for the treatment of emotional depression in a warm-blooded animal in need of such treatment comprising enteral or parenteral administration to said animal of a therapeutically effective amount of a compound according to claim 1 having the formula I defined in claim 1, or of a pharmaceutically acceptable acid addition salt thereof.

References Cited (Backward Citations)

US2633468A Cited
US3470192A Cited
DE1620315A1 Cited
GB1139146A Cited
US3751390A Cited
US3853899A Cited
GB1465581A Cited
US3890441A Cited
GB1465167A Cited
GB1510977A Cited
DE2653147A1 Cited
US4154743A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1984-03-30 1984-09-29 1985-03-31 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1988-03-30 1988-09-29 1989-03-31 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1992-03-30 1992-09-29 1993-03-31 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag